DE3881881T3 - Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe. - Google Patents

Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe.

Info

Publication number
DE3881881T3
DE3881881T3 DE3881881T DE3881881T DE3881881T3 DE 3881881 T3 DE3881881 T3 DE 3881881T3 DE 3881881 T DE3881881 T DE 3881881T DE 3881881 T DE3881881 T DE 3881881T DE 3881881 T3 DE3881881 T3 DE 3881881T3
Authority
DE
Germany
Prior art keywords
carrier
endothelial
diagnostic
vascular
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3881881T
Other languages
English (en)
Other versions
DE3881881D1 (de
DE3881881T2 (de
Inventor
David F Ranney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abeona Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25671864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3881881(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE3881881D1 publication Critical patent/DE3881881D1/de
Application granted granted Critical
Publication of DE3881881T2 publication Critical patent/DE3881881T2/de
Publication of DE3881881T3 publication Critical patent/DE3881881T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]
DE3881881T 1987-04-01 1988-03-30 Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe. Expired - Fee Related DE3881881T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/033,432 US4925678A (en) 1987-04-01 1987-04-01 Endothelial envelopment drug carriers
PCT/US1988/001096 WO1988007365A2 (en) 1987-04-01 1988-03-30 Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
CA000565119A CA1324080C (en) 1987-04-01 1988-04-26 Bioadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents

Publications (3)

Publication Number Publication Date
DE3881881D1 DE3881881D1 (de) 1993-07-22
DE3881881T2 DE3881881T2 (de) 1993-12-16
DE3881881T3 true DE3881881T3 (de) 1997-06-05

Family

ID=25671864

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3881881T Expired - Fee Related DE3881881T3 (de) 1987-04-01 1988-03-30 Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe.

Country Status (8)

Country Link
US (1) US4925678A (de)
EP (1) EP0352295B2 (de)
JP (1) JP2886171B2 (de)
AT (1) ATE90554T1 (de)
AU (1) AU607494B2 (de)
CA (1) CA1324080C (de)
DE (1) DE3881881T3 (de)
WO (1) WO1988007365A2 (de)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
WO1990003190A1 (en) * 1988-09-29 1990-04-05 Ranney David F Methods and compositions for magnetic resonance imaging
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
DE69027941T2 (de) * 1989-11-27 1997-01-23 Nippon Shinyaku Co Ltd Fettemulsion
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6989141B2 (en) 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (de) * 1990-04-02 1993-05-01 Sint Sa
AU647484B2 (en) * 1990-04-26 1994-03-24 Cytrx Corporation Composition and method for topical treatment of damaged or diseased tissue
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
AU707085B2 (en) * 1991-04-02 1999-07-01 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
FR2687071B1 (fr) * 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
AU4693093A (en) * 1992-07-27 1994-02-14 Haemacure Biotech Inc. Biocompatible surgical implant
JP3337075B2 (ja) * 1992-08-05 2002-10-21 名糖産業株式会社 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
PT619730E (pt) * 1992-10-08 2001-04-30 Supratek Pharma Inc Composicao de agentes anti-neoplasticos incorporados em micelas
US5362425A (en) * 1992-10-22 1994-11-08 Technology Unlimited, Inc. Organic oil spray-drying techniques
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP0684814B1 (de) * 1993-02-22 1998-06-17 Alza Corporation Mittel zur oralen gabe von wirkstoffen
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
CN1245156C (zh) * 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
EP0636363B1 (de) * 1993-07-27 2001-05-23 Terumo Kabushiki Kaisha Verabreichungssystem für Arzneistoffe
AU694135B2 (en) 1993-07-30 1998-07-16 Imcor Pharmaceutical Company Stabilized microbubble compositions for ultrasound
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
WO1996004922A1 (en) * 1994-08-10 1996-02-22 Davis, Joanne, T. Method of using hyaluronic acid for the detection, location and diagnosis of tumors
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
AU6104896A (en) * 1995-06-07 1996-12-30 Regents Of The University Of California, The Therapeutic microdevices and methods of making and using sam e
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
AU1074897A (en) 1995-11-08 1997-05-29 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
AU716667B2 (en) 1996-01-10 2000-03-02 Nycomed Imaging As Contrast media
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
ES2243994T5 (es) 1996-04-19 2009-10-29 Grifols Inc. Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
EP1369111A1 (de) * 1996-10-03 2003-12-10 Hermes Biosciences, Inc. Hydrophile Mikropartikel und Verfahren zu deren Herstellung
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
JP4272811B2 (ja) * 1997-09-05 2009-06-03 マルホ株式会社 関節内疾患治療用のナノカプセル製剤
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6338834B1 (en) 1998-04-30 2002-01-15 The Curators Of The University Of Missouri Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
AU4994899A (en) 1998-07-13 2000-02-01 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
AU5329599A (en) * 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
US6780397B2 (en) 1998-09-01 2004-08-24 Curators Of The University Of Missouri Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
US6299980B1 (en) 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating
US6379691B1 (en) 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
US6638974B1 (en) 1999-04-09 2003-10-28 University Of South Florida Ascorbyl esters for the treatment of cancer
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
DE60040299D1 (de) * 1999-06-14 2008-10-30 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
AU2002218744A1 (en) * 2000-07-11 2002-01-21 University Of South Florida Bax fragment induced tumor cell death
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7172770B2 (en) * 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US7731945B2 (en) * 2001-10-26 2010-06-08 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
EP1389487B1 (de) * 2002-07-16 2006-05-03 Seiko Epson Corporation Mikrokapselhaltige Zusammensetzung für elektrophoretische Anzeigen
WO2004037204A2 (en) * 2002-10-25 2004-05-06 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2005021065A2 (en) * 2003-08-29 2005-03-10 New York University Indirect delivery of growth factors into the central nervous system
US20050059610A1 (en) * 2003-09-12 2005-03-17 Paul Wischmeyer Glutamine for use in treating injury
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
EP1758998B1 (de) 2004-01-30 2010-12-15 Quark Pharmaceuticals, Inc. Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
KR101094617B1 (ko) 2004-08-16 2011-12-15 사일런스 테라퓨틱스 아게 알티피801 억제제의 치료적 용도
DE112005002270T5 (de) * 2004-09-28 2007-08-30 Osaka University Dreidimensionales Führungssystem und Verfahren, und Arznei-Zuführungssystem
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2007080129A1 (en) 2006-01-13 2007-07-19 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US20080260678A1 (en) * 2006-10-10 2008-10-23 University Of Colorado Molecular band-aid
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
DK2170403T3 (da) 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2742875B1 (de) 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Cyanoacrylgewebehaftstoffe
US8486528B2 (en) * 2008-01-22 2013-07-16 Gwangju Institute Of Science And Technology Temperature-sensitive nano-carriers
EP2106791A1 (de) 2008-03-31 2009-10-07 Biotempt B.V. Glutamin oder Glutamine enthaltendes Dipeptide in einer spezifischen Dosierung für die Behandlung von Entzündungen
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
US9149509B2 (en) 2009-03-26 2015-10-06 Henry Ford Health System Methods for improving neurological outcome after neural injury and neurodegenerative disease
EP2440214A4 (de) 2009-06-08 2013-07-31 Quark Pharmaceuticals Inc Verfahren zur behandlung chronischer nierenkrankheiten
WO2011066475A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
KR101692063B1 (ko) 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 hsp47 발현의 조절
EP2510098B1 (de) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des zns
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
EP2538951B1 (de) 2010-02-22 2020-04-22 Health Enhancement Products Inc. Mittel und mechanismen zur vorbeugung von hypercholesterinämie
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
KR101553753B1 (ko) 2010-06-24 2015-09-16 쿠아크 파마수티칼스 인코퍼레이티드 Ｒｈｏａ에 대한 이중 가닥 ｒｎａ 및 그의 용도
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
CN103298939A (zh) 2010-12-06 2013-09-11 夸克医药公司 包含位置修饰的双链寡核苷酸化合物
US9205100B2 (en) 2011-03-03 2015-12-08 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
SG10201604479YA (en) 2011-03-03 2016-07-28 Quark Pharmaceuticals Inc Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2776565A1 (de) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems
CN104080480A (zh) 2012-01-01 2014-10-01 奇比艾企业有限公司 用于选择性递送治疗剂和诊断剂的endo180靶向微粒
WO2013106494A1 (en) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
SI2854841T1 (sl) 2012-06-04 2017-06-30 Diamedica Inc. Glikozilacijske izooblike humanega tkivnega kalikreina-1
JP5918909B2 (ja) 2012-06-25 2016-05-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
EP2895608B1 (de) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Doppelsträngige oligonukleotidmoleküle an p53 und verfahren zur verwendung davon
CA2880290C (en) 2012-09-12 2020-10-27 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
CA2904978A1 (en) 2013-03-12 2014-10-09 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
EP3258948B1 (de) 2015-02-16 2023-12-06 Zivo Bioscience, Inc. Anti-entzündliche und immunomodulatorische zusammensetzungen, enthaltend klebsormidium und verwendungen davon
WO2017142906A1 (en) 2016-02-16 2017-08-24 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement
JP2020510023A (ja) 2017-03-09 2020-04-02 ダイアメディカ， インコーポレイテッド 組織カリクレイン１の剤形
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3922720A1 (de) 2020-06-09 2021-12-15 Universidad de Murcia Therapie zur verhinderung unerwünschter kardialer remodellierung nach einem akuten myokardinfarkt
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
DE3000483A1 (de) * 1979-01-09 1980-07-17 Fuji Photo Film Co Ltd Mikrokapseln fuer immunologische bestimmungen
CS216992B1 (en) * 1980-07-21 1982-12-31 Miroslav Stol Composite polymere material for the biological and medicinal utilitation and method of preparation thereof
JPS57130914A (en) * 1981-02-04 1982-08-13 Agency Of Ind Science & Technol Prolongation of activity retention
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
IL65131A0 (en) * 1982-02-28 1982-04-30 Yeda Res & Dev Process for the production of agarose-polyaldehyde beads and their biological applications
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2596399B1 (fr) * 1986-03-28 1988-09-02 Univ Rennes Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament

Also Published As

Publication number Publication date
EP0352295B2 (de) 1996-04-10
ATE90554T1 (de) 1993-07-15
US4925678A (en) 1990-05-15
CA1324080C (en) 1993-11-09
AU607494B2 (en) 1991-03-07
DE3881881D1 (de) 1993-07-22
EP0352295A1 (de) 1990-01-31
DE3881881T2 (de) 1993-12-16
JP2886171B2 (ja) 1999-04-26
WO1988007365A2 (en) 1988-10-06
EP0352295B1 (de) 1993-06-16
AU1627588A (en) 1988-11-02
JPH04504404A (ja) 1992-08-06
WO1988007365A3 (en) 1988-11-17

Similar Documents

Publication Publication Date Title
DE3881881T3 (de) Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe.
Lademann et al. Hair follicles as a target structure for nanoparticles
Edlich et al. Principles of emergency wound management
US5814599A (en) Transdermal delivery of encapsulated drugs
Danon et al. Promotion of wound repair in old mice by local injection of macrophages.
Yamashita et al. Scanning electron microscopic evaluation of the skin surface after ultrasound exposure
Currie Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.
Morantz et al. Macrophages in experimental and human brain tumors: Part 1: Studies of the macrophage content of experimental rat brain tumors of varying immunogenicity
ES2056832T5 (es) Vehiculo para la liberacion que contiene un agente activo asociado con una substancia anfifila.
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
NO884947D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk doseringsform med kontrollert frigjoerelse.
JP2003525641A (ja) 爪真菌症の治療用感圧接着性マトリックス・パッチ
Cardany et al. The crush injury: a high risk wound
CS9001136A2 (en) Method of transdermal therapeutical system's production with active substance's graded liberation and application for active substances' local or systemic administration
MC2025A1 (fr) Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
MX9200413A (es) Composicion farmaceutica para el tratamiento y/o diagnostico de tumores de tejido blando.
de ALMEIDA et al. Effect of the intraperitoneal and intracerebroventricular administration of ACTH, epinephrine, or β-endorphin on retrieval of an inhibitory avoidance task in rats
Jewell et al. Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis
WO1997033620A2 (de) Verbindungen zur behandlung von tumoren
ATE67672T1 (de) Protein c-inhibitor (pci) als pharmazeutikum und diagnostikum, verfahren zu herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci.
Ridley et al. British cosmetic regulations inadequate.
Jaworsky Analysis of cutaneous foreign bodies
ITRM910155A1 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: ACCESS PHARMACEUTICALS INC., DALLAS, TEX., US

8339 Ceased/non-payment of the annual fee